aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
3.020
-0.110 (-3.51%)
At close: Mar 31, 2025, 4:00 PM
3.025
+0.005 (0.17%)
After-hours: Mar 31, 2025, 7:55 PM EDT
aTyr Pharma Employees
As of December 31, 2023, aTyr Pharma had 59 total employees, including 56 full-time and 3 part-time employees. The number of employees decreased by 11 or -15.71% compared to the previous year.
Employees
59
Change (1Y)
-11
Growth (1Y)
-15.71%
Revenue / Employee
$3,983
Profits / Employee
-$1,085,136
Market Cap
268.35M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ATYR News
- 4 days ago - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewsWire
- 17 days ago - aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating - Seeking Alpha
- 17 days ago - aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - GlobeNewsWire
- 19 days ago - aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine - GlobeNewsWire
- 25 days ago - aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - GlobeNewsWire
- 27 days ago - aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results - GlobeNewsWire